Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cisplatin-induced changes in bleomycin elimination.

G C Yee, W R Crom, J E Champion

    Cancer Treatment Reports
    |June 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.

    British journal of cancer·2012
    Same author

    International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

    British journal of cancer·2009
    Same author

    Molecular analysis of gene amplification in tumors.

    Current protocols in human genetics·2008
    Same author

    Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas.

    Oncogene·2007
    Same author

    Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.

    Clinical pharmacology and therapeutics·2006
    Same author

    Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system.

    European journal of cancer (Oxford, England : 1990)·2001
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Bleomycin clearance decreases and its half-life increases in children with higher cumulative cisplatin doses. Renal clearance also declined, but serum creatinine and BUN levels were not reliable indicators of bleomycin elimination changes.

    Area of Science:

    • Pediatric Oncology
    • Pharmacokinetics
    • Cancer Therapeutics

    Background:

    • Bleomycin is a chemotherapy agent used in pediatric cancers.
    • Its use in combination with vinblastine and cisplatin is common.
    • Understanding bleomycin's disposition is crucial for optimizing treatment and minimizing toxicity in children.

    Purpose of the Study:

    • To investigate the pharmacokinetic disposition of bleomycin in pediatric patients undergoing multi-agent chemotherapy.
    • To assess the impact of cumulative cisplatin dose on bleomycin clearance and half-life.
    • To evaluate the relationship between renal function markers and bleomycin elimination.

    Main Methods:

    • Pharmacokinetic analysis of bleomycin disposition in two pediatric patients.
    • Data collected after at least six courses of vinblastine, bleomycin, and cisplatin.

    Related Experiment Videos

  • Measurement of plasma clearance, terminal-phase half-life, and renal clearance of bleomycin.

    • Main Results:

    • Total plasma clearance of bleomycin significantly decreased (from 39 to 18 ml/min/m2) with increasing cumulative cisplatin dose (>300 mg/m2).
    • The terminal-phase half-life of bleomycin increased (from 4.4 to 6.0 hrs) in these patients.
    • Renal clearance of bleomycin decreased in one patient (from 30 to 8.2 ml/min/m2), but serum creatinine and BUN levels did not predict these changes.

    Conclusions:

    • Cumulative cisplatin exposure appears to impair bleomycin elimination in pediatric patients.
    • Standard renal function tests may not adequately reflect changes in bleomycin clearance.
    • Further studies are needed to elucidate the mechanisms of bleomycin disposition changes and guide dose adjustments in pediatric oncology.